Tiny radioactive seeds aim to zap recurrent prostate cancer
NCT ID NCT07290998
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early study tests a new device called Alpha DaRT, which places tiny radioactive seeds directly into prostate tumors that have returned after initial treatment. The main goal is to see if it's safe, with a secondary look at whether it can control the cancer. Up to 12 men with locally recurrent prostate cancer will be enrolled.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Diffusing Alpha Radiation Emitters (DaRT) seeds
- What this could lead to
- If successful, this could offer a new, targeted radiation option for men with recurrent prostate cancer, potentially controlling the disease without more invasive treatments.
- What could go wrong
- This is a very small, early safety study with only 12 participants. It may not show clear effectiveness, and there could be unexpected side effects from the radioactive seeds.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY RECURRENT PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tracer light up hidden prostate cancer?
- Could deep breaths before surgery ward off Post-Op confusion?
- A second look: MRI screening may spot hidden prostate cancers
- Can precision protons spare the bowel in prostate cancer?
- AI coaches doctors on cancer risk talks
- Can an immune booster make hormone therapy work better against prostate cancer?